Medtronic (MDT) is back in focus after fresh U.S. Food and Drug Administration clearance for its AI-enabled Stealth AXiS surgical system in cranial and ENT procedures, along with encouraging ALERT trial results for AI-driven cardiac care support.

Despite the recent AI and FDA milestones, the 1 month share price return of 12.27% and year to date share price return of 10.40% show pressure building on the US$86.06 share price. At the same time, the 3 year total shareholder return of 18.19% contrasts with a 5 year total shareholder loss of 16.89%, suggesting momentum has been choppy over different timeframes.

If you like the AI angle in healthcare but want to see what else is out there, it is worth scanning 33 healthcare AI stocks as potential follow up ideas.

With Medtronic trading at US$86.06 alongside mixed multi year returns and an indicated discount to some valuation estimates, is the recent AI and FDA news creating a genuine entry point or is the market already pricing in future growth?

Most Popular Narrative: 9.4% Undervalued

According to the most followed narrative, Medtronic's fair value sits at $95.00 versus the current $86.06 share price, which frames recent AI progress against a modest valuation gap.

With an annual R&D investment of ~$2.7 billion (9% of revenue), Medtronic maintains a strong pipeline, including breakthroughs like the Hugo robotic-assisted surgery system (competing with Intuitive Surgical’s da Vinci) and the MiniMed 780G insulin pump. Recent FDA approvals, such as the PulseSelect AF ablation system, underscore innovation momentum.

Want to see what underpins that fair value gap? The narrative leans heavily on sustained product investment, margin support and a future earnings profile more often associated with faster growing peers.

Result: Fair Value of $95.00 (UNDERVALUED)

However, recall risk and FDA approval delays around devices like insulin pumps or robotics, as well as pressure in the diabetes unit, could quickly challenge that undervalued thesis.

Next Steps

Curious whether the article's cautious tone matches your own view of Medtronic? Act quickly, review the full picture, and weigh up the company's 6 key rewards.

Looking for more investment ideas?

If Medtronic has sharpened your interest in healthcare and quality, do not stop here. Broaden your watchlist now using focused screeners built around fundamentals and risk.

• Pinpoint reliable cash generators by scanning companies in the 63 high quality undervalued stocks that pair quality fundamentals with potential pricing gaps.
• Prioritize resilience by reviewing the 65 resilient stocks with low risk scores to see which businesses stand out on lower risk scores and sturdier profiles.
• Spot future standouts early by checking the screener containing 25 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.